Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine c...

Full description

Bibliographic Details
Main Authors: Rodriguez, Pedro C, Neninger, Elia, García, Beatriz, Popa, Xitlally, Viada, Carmen, Luaces, Patricia, González, Gisela, Lage, Agustin, Montero, Enrique, Crombet, Tania
Format: Online
Language:English
Published: BioMed Central 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215653/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215653/

Similar Items